NCT06994195 2026-04-20
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
Clinical Trials
12 trialsNCT07213804 2026-04-17
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT05659381 2026-04-16
HOTT
GOG Foundation
Phase 3 Recruiting
NCT06824467 2026-04-16
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06915025 2026-04-13
OVATION-3
Imunon
Phase 3 Recruiting
NCT05281471 2026-03-18
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Phase 3 Recruiting
NCT04575935 2026-03-05
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT05445778 2026-02-23
GLORIOSA
AbbVie
Phase 3 Recruiting
NCT04111978 2025-09-29
MATAO
Swiss GO Trial Group
Phase 3 Recruiting
NCT05009082 2025-09-10
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Phase 3 Recruiting
NCT06834672 2025-04-13
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Recruiting
NCT05737303 2025-02-11
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Phase 3 Recruiting